Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

Completed · Phase 1 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07242813 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms.

Key facts

Study ID

NCT04668066

Run by

Pfizer

People needed

121

Starts

2020-12-10

Expected to finish

2022-12-27

Last updated by the study team

2024-06-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• First OC Dermatology — Fountain Valley, California, United States
• Keck School of Medicine of USC — Los Angeles, California, United States
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Orange County Research Center — Tustin, California, United States
• Vital Prospects Clinical Research Institute, PC — Tulsa, Oklahoma, United States
• Aspen Clinical Research — Orem, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.